Since the start of the pandemic, Exonbio has developed SARS-CoV-2 recombinant rabbit antibodies using its proprietary single plasma cell interrogation (SPIN) platform. The firm has screened hundreds of clones of rabbit mAbs by surface plasmon resonance with Biacore 3000 and identified high-affinity clones against the recombinant full-length nucleocapsid protein of SARS-CoV-2.

Researchers identified 12 clones with a half maximal effective concentration (EC50) of less than 1 ng/mL, with the most potent clone being 6F2 at EC50 of 0.37 ng/mL (2.5 pM). Epitope mapping pointed to at least five well-separated epitopes so there are multiple choices for selecting the pairs for sandwich enzyme-linked immunosorbent assay (ELISA). In addition, there are choices for other applications that require a pair of antibodies as well.

New tools rapidly detect anti-SARS-CoV-2 antibodies
New tools using surrogate viruses may be useful for rapid testing to determine whether antibodies effectively neutralize SARS-CoV-2. The viral vector-based...

Shape-shifting may provide coronavirus with a survival advantage
Conformational changes of the SARS-CoV-2 spike protein -- the target of many vaccines and therapies -- may have features that help the virus hide from...

Oragenics identifies SARS-CoV-2 neutralizing antibodies
A stabilized prefusion spike protein licensed by Oragenics has generated neutralizing antibodies in mice during immunization against SARS-CoV-2, according...

Replicating RNA COVID-19 vaccine shows robust responses in early testing
A replicating RNA vaccine delivered with a lipid-based nanoparticle emulsion has been shown to produce potent antibodies against SARS-CoV-2 in mice and...

NIH forms COVID-19 clinical trials network
The National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health (NIH), has established a new clinical trials...